A Multi Centre Open Label Single Therapy Dose Ranging Study to Characterise the Pharmacokinetics and Tolerability of BTDS 5-20 ug/h in Children Who Require Opioid Analgesia for Moderate to Severe Mouth Pain Secondary to Chemotherapy Induced Mucositis.
Phase of Trial: Phase I/II
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Buprenorphine (Primary)
- Indications Pain
- Focus Pharmacokinetics
- 01 Nov 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 23 Oct 2012 Planned End Date changed from 1 Apr 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 07 Jul 2012 Additional trial location (Denmark) added as reported by European Clinical Trials Database record.